Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 2/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 11/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217352 | 0.97 | FOLH1 (0.60) | NPY4RNPY1RNPY2RFOLH1BACE1 | |
| SCHEMBL30464728 | 0.96 | NPY1R (0.60) | NPY4RNPY1RNPY2RFOLH1BACE1 | |
| SCHEMBL29350874 | 0.93 | FOLH1 (0.68) | NPY4RNPY1RNPY2RFOLH1OPRM1 | |
| SCHEMBL8332107 | 0.92 | FOLH1 (0.58) | NPY4RNPY1RNPY2RFOLH1BACE1 | |
| SCHEMBL8332105 | 0.92 | FOLH1 (0.58) | NPY4RNPY1RNPY2RFOLH1BACE1 | |
| SCHEMBL30352847 | 0.92 | BACE1 (0.65) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL30352879 | 0.92 | BACE1 (0.65) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL31636210 | 0.92 | BACE1 (0.55) | NPY4RNPY1RNPY2RFOLH1BACE1 | |
| SCHEMBL29463738 | 0.92 | NPY1R (0.57) | NPY4RNPY1RNPY2RFOLH1BACE1 | |
| SCHEMBL8837270 | 0.91 | BACE1 (0.61) | NPY4RNPY1RNPY2RFOLH1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240272146-A1 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | AAT BIOQUEST, INC. | 2024-08-15 | — | — | US | claimed |
| US-12618847-B2 | Activity-based probes with unnatural amino acids to monitor proteasome activity | PURDUE RESEARCH FOUNDATION (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240272146-A1 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | AAT BIOQUEST, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-3746440-B1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | UNIV TEXAS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-RE49518-E1 | Fluorescent probe for detecting calpain activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20230108494-A1 | ACTIVITY-BASED PROBES WITH UNNATURAL AMINO ACIDS TO MONITOR PROTEASOME ACTIVITY | PURDUE RESEARCH FOUNDATION | 2023-04-06 | — | — | US | disclosed |
| US-20220332758-A1 | PEPTIDE-BASED COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | NATIONAL INSTITUTES OF HEALTH | 2022-10-20 | — | — | US | disclosed |
| EP-4028038-A1 | PEPTIDE-BASED COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Board of Regents, The University of Texas System (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-110079300-B | Nano-phosphorescent probe and application thereof | 苏州大学 | 2022-07-05 | — | — | CN | disclosed |
| US-11357817-B2 | Immunoproteasome inhibitor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1805208-A2 | LABELED COMPOUNDS FOR PROTEASOME INHIBITION | Proteolix, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1745064-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | Proteolix, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006045066-A2 | LABELED COMPOUNDS FOR PROTEASOME INHIBITION | PROTEOLIX, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060088471-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2006-04-27 | — | — | US | disclosed |
| WO-2005105827-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245435-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20040266664-A1 | Enzyme inhibition | YALE UNIVERSITY | 2004-12-30 | — | — | US | disclosed |
| US-6831099-B1 | Irreversible inhibitors distinct from those reagents currently; antitumor, anti-inflammatory; peptide alpha ', beta '-epoxides and peptide alpha ', beta '-aziridines | YALE UNIVERSITY | 2004-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332758-A1 | PEPTIDE-BASED COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, IAPP, BACE1 | NPY4R 151/4885NPY1R 108/4885NPY2R 160/4885 |
| US-11357817-B2 | Immunoproteasome inhibitor | SERPINB1, PSMB1, PSMB11 | NPY4R 4618/4885NPY1R 4387/4885NPY2R 4553/4885 |
| US-20060088471-A1 | Compounds for enzyme inhibition | DNPEP, ANPEP, CPN1 | NPY4R 3482/4885NPY1R 2284/4885NPY2R 2936/4885 |
| US-20240272146-A1 | CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTION | ANTXR2, CDYL, VIP | NPY4R 945/4885NPY1R 571/4885NPY2R 1029/4885 |
| US-20050245435-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | NPY4R 3333/4885NPY1R 2519/4885NPY2R 2898/4885 |
| US-12618847-B2 | Activity-based probes with unnatural amino acids to monitor proteasome activity | PSMB1, PSMB11, PSMB3 | NPY4R 2453/4885NPY1R 1732/4885NPY2R 2883/4885 |
| US-20040266664-A1 | Enzyme inhibition | DNPEP, ANPEP, PREP | NPY4R 4482/4885NPY1R 3840/4885NPY2R 4316/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | NPY4R 3333/4885NPY1R 2519/4885NPY2R 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.